Publication Date 01/07/2014         Volume. 6 No. 6   
Information to Pharmacists

Editorial

From the desk of the editor

Welcome to the July 2014 homepage edition of i2P (Information to Pharmacists) E-Magazine.
At the commencement of 2014 i2P focused on the need for the entire profession of pharmacy and its associated industry supports to undergo a renewal and regeneration.
We are now half-way through this year and it is quite apparent that pharmacy leaders do not yet have a cohesive and clear sense of direction.
Maybe the new initiative by Woolworths to deliver clinical service through young pharmacists and nurses may sharpen their focus.
If not, community pharmacy can look forward to losing a substantial and profitable market share of the clinical services market.
Who would you blame when that happens?
But I have to admit there is some effort, even though the results are but meagre.
In this edition of i2P we focus on the need for research about community pharmacy, the lack of activity from practicing pharmacists and when some research is delivered, a disconnect appears in its interpretation and implementation.

read more
open full screen

Recent Comments

Click here to read...

Under the influence of magnetic drugs

Staff Researcher

articles by this author...

Editing and Researching news and stories about Australian and International Pharmacy Issues

For more than three decades scientists have been investigating magnetic nanoparticles as a method of drug delivery. Now by combining three metals - iron, gold and platinum - pharmacists at the University of Sydney believe they have discovered a method for magnetically directing drugs through the body.

open this article full screen

The discovery has been published online in the international journal Inorganica Chimica Acta.

Led by Dr Nial Wheate, a team of scientists from the Faculty of Pharmacy, along with collaborators in Scotland, have developed a new anticancer drug that has an iron oxide core as small as 5 nanometres in size (1/1000th the width of a human hair).

Dr Nial Wheate: "This discovery means we can potentially direct where in the body a drug goes."

The discovery has been published online today in the international journal Inorganica Chimica Acta.

Led by Dr Nial Wheate, a team of scientists from the Faculty of Pharmacy, along with collaborators in Scotland, have developed a new anticancer drug that has an iron oxide core as small as 5 nanometres in size (1/1000th the width of a human hair).

"We coated this iron oxide core in a protective layer of gold before cisplatin, a platinum drug that revolutionised the treatment of testicular cancer, was attached to the gold coating using spaghetti-like strings of polymer."

The important thing about this new drug, says Dr Wheate, is the ability of its iron core to move under the influence of a magnet; similar to the iron filing experiments many people have performed in science classes.

"When we take regular medication it is difficult to manage where it goes. But this discovery means we can potentially direct exactly where in the human body a drug goes. We can move it to the desired cancer tumour site using powerful magnetic fields. Otherwise, a strong magnet could be implanted into a tumour, and draw the drug into the cancer cells that way."

The technology was demonstrated when the team grew cancer cells in plates in the lab. When they placed a magnet under the plates, the drug affected and killed only those cells growing near the magnet, leaving the others unharmed, says Dr Wheate.

"Many of the side-effects associated with chemotherapy occur because the drugs spread throughout the body, killing healthy organs as well as cancers.

"Ultimately, this technology could greatly reduce or even eliminate the severe side-effects that people associate with chemotherapy such as hair loss, nausea, vomiting, low red blood cells and an increased risk of infection."

This new drug technology could also be used to treat a range of cancers that have not been treatable with conventional platinum drugs, like prostate cancer.

Platinum drugs are one of the most regularly used family of agents in chemotherapy and include cisplatin, carboplatin and oxaliplatin.

Return to home

Post new comment

The content of this field is kept private and will not be shown publicly.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Allowed HTML tags: <a> <em> <strong> <cite> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Lines and paragraphs break automatically.

More information about formatting options

CAPTCHA
This question is for testing whether you are a genuine visitor, to prevent automated spam submissions.
Incorrect please try again
Enter the words above: Enter the numbers you hear:
  • Copyright (C) 2000-2014 Computachem Services, All Rights Reserved.

Website by Ablecode